Methyl-1-Testosterone (M1T)
Methyl-1-testosterone (M1T) is a 17α-methylated derivative of 1-testosterone (dihydroboldenone) that was sold as a 'prohormone' in the mid-2000s. It is extremely potent by milligram, giving fast dry mass and strength, but is correspondingly harsh: strongly hepatotoxic, heavily suppressive and often accompanied by lethargy and malaise.
01 Overview
M1T reached the supplement market after earlier prohormone bans and became notorious for how strong it was relative to its low milligram doses. Structurally it combines the 1-ene modification of boldenone-type steroids with 17α-methylation for oral activity.
Users describe rapid, dry gains in strength and lean mass rivalling injectables, but also frequent side effects out of proportion to the dose: strong lethargy, loss of libido, aggression and a heavily strained liver. Human data are limited to anecdote and case reports, so effects are rated accordingly.
02 Mechanism
Androgen-receptor agonist derived from 1-testosterone (a non-aromatising 1-ene androgen) with 17α-methylation for oral bioavailability; high AR affinity gives strong per-milligram potency.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 5–10 mg/day | Oral | Even low doses are strongly active. |
| Common | 10–20 mg/day | Oral | Typical historical range; side effects common. |
| Heavy | 20–30 mg/day | Oral | High risk; severe hepatic strain and malaise. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Rapid dry mass and strengthFast lean-mass and strength gains at very low milligram doses. | Anecdotal | ||
| No aromatisationThe 1-ene, non-aromatising structure avoids oestrogenic bloat. | Anecdotal | ||
| Lethargy and malaiseStrong fatigue, low libido and general malaise are commonly reported. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Adverse lipid changes and blood pressureStrong HDL suppression and elevated blood pressure. | Moderate | Very common | Anecdotal | |
| Severe hepatotoxicityCase reports of significant hepatic injury; considered one of the harsher prohormone-era orals. | Severe | Common | Observational | |
| HPTA suppressionHeavy suppression of endogenous testosterone with associated lethargy and low libido. | Severe | Universal | Observational |